Fig. 6

Effects of RSG on PA-induced cytotoxicity in HepG2 cells and HUVECs. a and b MTT assay of (a) HepG2 cells and (b) HUVECs treated with PA for 24 h with or without RSG pre-treatment. c-f ORO staining of (c and d) HepG2 cells and (e and f) HUVECs. Cells were pre-treated with 20 μM RSG for 2 h, and then treated with 0.2 or 0.4 mM PA for 24 h. c and e Scale bar, 100 μm. d and f Quantifications of neutral lipids in cells stained with ORO were also presented. Data are presented as the mean ± standard deviation of three independently prepared samples, each with three measurements. ^*P < 0.05 and ^**P < 0.01 vs. control group; ^$$P < 0.01 vs. 0.2 mM-PA group; ^##P < 0.01 vs. 0.4 mM-PA group. RSG, rosiglitazone; PA, palmitic acid; ORO, oil red O; HUVECs, human umbilical vein endothelial cells